Sobi Raises FY26 Revenue Growth Guidance

03:22 AM EDT, 10/27/2026 (MT Newswires) -- Swedish Orphan Biovitrum (SOBI.ST), or Sobi, lifted its revenue growth guidance for full-year 2026, according to a Tuesday release. The Swedish pharmaceuticals company now expects revenue to increase by high-teens to low-20% at constant exchange rate, compared with a mid- to high-teens percentage growth projected previously.